News

Novo Nordisk logo on a window

Business Strategy

Novo on the ‘ins and outs’ of its nucleic acid growth Novo on the ‘ins and outs’ of its nucleic acid growth

With a mix of feasibility study alliances, R&D collaborations, and outright M&A, Novo Nordisk’s presence in the RNA and gene therapy space now complements its core peptide and protein portfolio.

byDan Stanton, Editorial director

Jan 16, 2025

|

5 Min Read

JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn

byMillie Nelson

Jan 15, 2025

2 Min Read

JPM written on wooden blocks in blue

JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx

byMillie Nelson

Jan 14, 2025

2 Min Read

Image of China banknotes with a magnifying glass indicating dealmaking in Asia

Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung

Jan 8, 2025

5 Min Read

2025 wooden blocks

Takeovers, Trump, and trends: how biopharma is likely to shift this year Takeovers, Trump, and trends: how biopharma is shifting this year

byJonathan Smith

Jan 1, 2025

5 Min Read

Charles River launches UK incubator program Charles River launches UK incubator program

byMillie Nelson

Dec 28, 2024

2 Min Read

Two cartoons pushing puzzle pieces together

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m

Chroma Medicine and Nvelop Tx merge to launch nChroma Bio with $75m

byMillie Nelson, Editor

Obesity on a board

Antag bags $84M in series A funding to drive obesity candidate to the clinic

Antag bags $84M in series A funding to drive obesity candidate to the clinic

byMillie Nelson, Editor

M&A on wooden blocks

AbbVie forks out $200m to buy Roche spin-out Nimble

AbbVie forks out $200m to buy Roche spin-out Nimble

byMillie Nelson, Editor

2024 on a road

Megadeals continued amid sluggish investments and M&A in 2024

Megadeals continued amid sluggish investments and M&A in 2024

byJonathan Smith

Asia currency

Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset

Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset

byRichard Daverman, Editor

China on a clock

A growing phenomenon: The rise of biopharma NewCos in China

A growing phenomenon: The rise of biopharma NewCos in China

byRichard Daverman, Editor

plan prepare perform

‘Luck only comes to the most prepared people,’ says AltruBio CEO

‘Luck only comes to the most prepared people,’ says AltruBio CEO

byMillie Nelson, Editor

Trust on a dial

Three’s a crowd? Not in this partnership, says MicroFluidX

Three’s a crowd? Not in this partnership, says MicroFluidX

byMillie Nelson, Editor

Berlin on written wooden block

Bayer expands global incubator network with Germany hub

Bayer expands global incubator network with Germany hub

byMillie Nelson, Editor

Data

To protect the future of healthcare, we need to be data-driven

To protect the future of healthcare, we need to be data-driven

byMillie Nelson, Editor

Currency

Eyes on Asia: Merck and BioNTech land Chinese bispecifics

Eyes on Asia: Merck and BioNTech land Chinese bispecifics

byRichard Daverman, Editor

The ELA'S 2024

LSX awards the crème de la crème of dealmaking

LSX awards the crème de la crème of dealmaking

byMillie Nelson, Editor

M&A note

Novartis chases muscular dystrophy treatment with Kate Tx buy

Novartis chases muscular dystrophy treatment with Kate Tx buy

byMillie Nelson, Editor

Novo Nordisk sign

Business Strategy

Lessons and blessings: The Novo Nordisk way

Lessons and blessings: The Novo Nordisk way

byMillie Nelson, Editor

A whiteboard saying transition

From Series A to B: Navigating the transition from promise to proof

From Series A to B: Navigating the transition from promise to proof

byMillie Nelson, Editor

Shaking hands

Picky pharma prone to better proven partners amid dealmaking downturn

Picky pharma prone to better proven partners amid dealmaking downturn

byMillie Nelson, Editor

Money

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

byRichard Daverman, Editor

Panelists Anta Gkelou Partner, Sofinnova Partners; Bobby Soni CIO, BioInnovation Institute; Renee Lucander CEO, Calliditas Therapeutics

Successful mentorship between investors and CEOs hangs on respect

Successful mentorship between investors and CEOs hangs on respect

CMO Summit in Milan, Italy

IPOs on course for recovery but does biotech need public funding anymore?

IPOs on course for recovery but does biotech need public funding anymore?

byDan Stanton, Editorial director

coloured pencils

Nonprofit looks to bring tomorrow’s science into today’s classrooms

Nonprofit looks to bring tomorrow’s science into today’s classrooms

byMillie Nelson, Editor

Europe’s adversity to risk is why the US is ahead, say experts

Europe’s adversity to risk is why the US is ahead

byMillie Nelson, Editor

Money

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

byRichard Daverman, Editor

Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange

Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange

byRichard Daverman, Editor

Picture with women's health written on a card in pink

Call for specific female health funding to tackle biotech finance gender gap

Call for specific female health funding to tackle biotech finance gender gap

byMillie Nelson, Editor

Alzheimer's disease written in blocks

AbbVie forks out $1.4bn to buy Alzheimer’s therapy developer Aliada

AbbVie forks out $1.4bn to buy Aliada

byMillie Nelson, Editor

What’s your secret sauce? VC’s on what makes a compelling pitch

VC’s on what makes a compelling pitch

byMillie Nelson, Editor

Asian currency

Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

byRichard Daverman, Editor

'Is the worst behind us?' Financial expert talks biotech funding

'Is the worst behind us?' Financial expert talks biotech funding

byBrian Scanlan, Dan Stanton

From east to west: Lilly plans incubators in China and UK

From east to west: Lilly plans incubators in China and UK

byMillie Nelson, Richard Daverman

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.